(Q37769645)

22 August 2017

1 reference

title

Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours (English)

1 reference

22 August 2017

1 reference

Patrick Beauchesne

1

1 reference

22 August 2017

2 July 2010

1 reference

Lancet Oncology Commission

22 August 2017

1 reference

22 August 2017

11

1 reference

22 August 2017

9

1 reference

22 August 2017

871-879

1 reference

Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Combined-modality treatment of leptomeningeal gliomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Chemotherapy in neoplastic meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Low cerebrospinal fluid pressure syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Neoplastic meningitis-related prognostic significance of the Karnofsky performance status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Neoplastic meningitis-related encephalopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: Prolonged remission with the ommaya reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Leukoencephalopathy and Elevated Levels of Myelin Basic Protein in the Cerebrospinal Fluid of Patients with Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal N, N', N"-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal topotecan in adult patients with neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal mafosfamide: a preclinical pharmacology and phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal 5-fluoro-2'-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Clinical trial of intrathecal administration of 5-fluoro-2'-deoxyuridine for treatment of meningeal dissemination of malignant tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Continuous intrathecal administration of 5-fluoro-2'-deoxyuridine for the treatment of neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

New aspects of immunotherapy of leptomeningeal metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970034-6

7 January 2021

10.1016/S1470-2045(10)70034-6

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20598636